RespireRx

From WikiMD's WELLNESSPEDIA

RespireRx (formerly known as Cortex Pharmaceuticals) is a biopharmaceutical company that focuses on the discovery and development of drugs for the treatment of neurological and psychiatric disorders. The company's primary focus is on the development of drugs that modulate the activity of specific neurotransmitters in the brain.

History[edit]

RespireRx was originally founded as Cortex Pharmaceuticals in 1987. The company changed its name to RespireRx in 2015 to reflect its new focus on the development of drugs for the treatment of respiratory disorders, including sleep apnea and opioid-induced respiratory depression.

Research and Development[edit]

RespireRx's research and development efforts are focused on two main areas: the modulation of the GABA (gamma-aminobutyric acid) system and the modulation of the glutamate system. The company's GABA-related research is focused on the development of drugs that can enhance the activity of GABA, the primary inhibitory neurotransmitter in the brain. This research has led to the development of a number of potential drugs, including dronabinol, a synthetic form of cannabinoid that is currently in Phase II clinical trials for the treatment of sleep apnea.

The company's glutamate-related research is focused on the development of drugs that can inhibit the activity of glutamate, the primary excitatory neurotransmitter in the brain. This research has led to the development of ampakines, a class of drugs that can enhance the activity of the AMPA receptor, a type of glutamate receptor. Ampakines are currently in preclinical development for the treatment of a variety of neurological and psychiatric disorders, including schizophrenia, depression, and Alzheimer's disease.

Financials[edit]

As a publicly traded company, RespireRx is required to disclose its financial information to the public. The company's financial reports can be found on its website and on the website of the U.S. Securities and Exchange Commission.

See Also[edit]


This biopharmaceutical related article is a stub. You can help WikiMD by expanding it.

Stub icon

This neuroscience article is a stub. You can help WikiMD by expanding the page.

Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=RespireRx&oldid=5370145"